PRILOSEC (omeprazole) by AstraZeneca is proton pump inhibitors [moa]. First approved in 1989.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
PRILOSEC (omeprazole) is a proton pump inhibitor (PPI) that reduces gastric acid production by blocking H+/K+-ATPase in parietal cells. It is indicated for treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and acid-related conditions. The drug has become a standard-of-care agent across multiple GI indications since its 1989 approval.
Brand is in late-stage decline with limited growth opportunity; team focus is on market defense and line extension rather than expansion.
Proton Pump Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal
A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants
Pharmacokinetic Effect of Y-3 on Repaglinide,Warfarin and Omeprazole in Healthy Participants
Worked on PRILOSEC at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PRILOSEC offers limited career growth due to mature/LOE lifecycle status and minimal linked job openings. Roles focus on legacy brand management, generic containment, and OTC channel optimization rather than innovation or expansion.